Here is a list of recommended readings about psychotherapeutic ketamine, organized by topic. Please think of this list as a “tasting menu” of various important aspects of therapeutic ketamine treatment. This list will be updated periodically. This website also has a list of books about psychotherapeutic ketamine, and a list of articles that cite Dr. Bennett specifically. For more info, you can find many additional articles on PubMed, and you can search for past, current and future clinical trial on ClinicalTrials.gov.
PUBLISHED GUIDELINES
American Association of Nurse Anesthesiology (2023). AANA APNA Joint Position Statement on Ketamine Infusion Therapy for Psychiatric Disorders. AANA website.
https://www.aana.com/practice/clinical-practice/clinical-practice-resources/ketamine-infusion-therapy/
Bennett, R. (2020). Ethical guidelines for ketamine clinicians. Journal of Psychedelic Psychiatry, 2(4), 19-20.
https://www.journalofpsychedelicpsychiatry.org
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. American Journal of Psychiatry (03/17/21).
doi.org/10.1176/appi.ajp.2020.20081251
Sanacora, G., Frye, M. A., McDonald, W., et al. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399-405. DOI: 10.1001/jamapsychiatry.2017.0080
https://adaa.org/sites/default/files/Ketamine%20JAMA%20Journal%20Article%20-%20Charlie%20Nemeroff.pdf
U.S. Food & Drug Administration (2023). FDA warns patients and health care providers about potential risks associated with compounded ketamine products, including oral formulations, for the treatment of psychiatric disorders. FDA website.
https://www.fda.gov/drugs/human-drug-compounding/fda-warns-patients-and-health-care-providers-about-potential-risks-associated-compounded-ketamine
HISTORICAL PAPERS
Bennett, R. (2019). Paradigms of ketamine treatment. MAPS Bulletin, 29(1).
https://maps.org/news/bulletin/articles/436-maps-bulletin-spring-2019-vol-29,-no-1/7718-paradigms-of-ketamine-treatment-spring-2019
Denomme, N. (2018). The Domino Effect: Ed Domino’s early studies of psychoactive drugs. Journal of Psychoactive Drugs, 50(4), 298-305. DOI: 10.1080/02791072.2018.1506599
https://www.tandfonline.com/doi/full/10.1080/02791072.2018.1506599
Diamond, P. R., Farmery, A. D., Atkinson, S., et al. (2014). Ketamine infusions for treatment resistant depression: A series of 28 patients treated weekly or twice weekly in an ECT clinic. Journal of Psychopharmacology. 28(6), 536-544.
https://doi:10.1177/0269881114527361
Dickey, H., Jenkins, D. & Butler, F. (2012). Pre-hospital use of ketamine in battlefield analgesia. U.S. Defense Health Board.
https://apps.dtic.mil/sti/pdfs/AD1029081.pdf
Domino, E. (1965). Taming the Ketamine Tiger. Republished in Anesthesiology (Sept 2010, vol 113), 678-684.
https://doi.org/10.1097/ALN.0b013e3181ed09a2
Oaklander, M. (2017). New hope for depression. TIME.
https://time.com/magazine/us/4876068/august-7th-2017-vol-190-no-6-u-s/
Ryan, W. C., Marta, C. J. & Koek, R. J. (2014). Ketamine and depression: A review. International Journal of Transpersonal Studies, 33(2), 40-74.
http://dx.doi.org/10.24972/ijts.2014.33.2.40
Sewell, A. (2007). Ketamine: Peril and promise. MAPS Bulletin, XVII (1).
https://maps.org/news-letters/v17n1-html/ketamine-peril_and_promise.html
EFFICACY
Ahuja, S., Brendle, M., Smart, L. et al. (2022). Real-world depression, anxiety and safety outcomes of intramuscular ketamine treatment: A retrospective descriptive cohort study. BMC Psychiatry 22(634).
https://doi.org/10.1186/s12888-022-04268-5
Anand, A., Mathew, S. J., Sanacora, G., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. New England Journal of Medicine, 388(25), 2315-2325.
https://www.nejm.org/doi/pdf/10.1056/NEJMoa2302399
Bonnett, C., Jane, R., Ross, C. et al. (2021) Intramuscular ketamine to treat major depressive disorder: A case series of forty patients. Journal of Psychiatry and Mental Health, 6, 1-4. DOI: 10.16966/2474-7769.145
https://www.sciforschenonline.org/journals/psychiatry-mental-health/article-data/JPMH145/JPMH145.pdf
Molero, P., Ramos-Quiroga, J. A., Martin-Santos, R. et al. (2018). Antidepressant efficacy and tolerability of ketamine and esketamine: A critical review. CNS Drugs 32.
https://doi.org/10.1007/s40263-018-0519-3
SAFETY PROFILE & SIDE EFFECTS & INTERACTIONS
Acevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., et al. (2019). Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of Affective Disorders.
https://doi.org/10.1016/j.jad.2019.11.028
Andrashko, V., Novak, T., Bunovsky, M., et al. (2020). The antidepressant effect of ketamine is dampened by concomitant benzodiazepine medication. Frontiers in Psychiatry.
https://doi.org/10.3389/fpsyt.2020.00844
Bennett, R. & Yavorsky, C. (2021). Op-Ed: Mind the Ketamine Education Gap – Better training can prevent adverse outcomes in psychiatric patients. MedPage Today.
https://www.medpagetoday.com/psychiatry/depression/91719?trw=no
Feifel, D., Dadiomov, D., & Lee, K. (2020). Safety of repeated administration of parenteral ketamine for depression. Pharmaceuticals, 13(7).
https://doi.org/10.3390/ph13070151\
Morgan, C. J. A., & Curran, H. V. (2011). Ketamine use: A review. Addiction, 107(1), 27–38. DOI: 10.1111/j.1360-0443.2011.03576.x
https://pubmed.ncbi.nlm.nih.gov/21777321/
Pal, R., Balt, S., Erowid, E., et al. (2013). Ketamine is associated with lower urinary tract signs and symptoms. Drug and Alcohol Dependence. 132(1-2), 189-194. DOI: 10.1016/j.drugalcdep.2013.02.005
https://www.sciencedirect.com/science/article/abs/pii/S0376871613000422
Short, B., Fong, J., Galvez, V., et al. (2018). Side-effects associated with ketamine use in depression: A systematic review. The Lancet Psychiatry, 5(1), 65-78. DOI: 10.1016/S2215-0366(17)30272-9.
http://www.kaimacdonald.com/wp-content/uploads/2018/04/Short-2017-common-side-effects-with-ketamine-for-depression-w.pdf
PHARMACOLOGY
Dao, R. & Aggarwal, A.(2023). Utilization of ketamine for major depression. Journal of Exploratory Research in Pharmacology, 8(4), 342-347. DOI: 10.14218/JERP.2023.00027
https://www.xiahepublishing.com/2572-5505/JERP-2023-00027
Natoli, S. (2021). The multiple faces of ketamine in anaesthesia and analgesia. Drugs in Context.
https://doi.org/10.7573/dic.2020-12-8
BRAIN IMAGING
Ionescu, D. F., Felicione, J. M., Gosai, A., et al. (2018). Ketamine-associated brain changes: A review of the neuroimaging literature. Harvard Review of Psychiatry. 26(6), 320-339. DOI: 10.1097/HRP.0000000000000179
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102096/
KETAMINE-ASSISTED PSYCHOTHERAPY
Breeksema, J. J., Niemeijer, A., Kuin, B., et al. (2022). Holding on or letting go? Patient experiences of control, context, and care in oral esketamine treatment for treatment-resistant depression: A qualitative study. Frontiers in Psychiatry, 13:948115.
https://doi.org/10.3389/fpsyt.2022.948115
Gold, V. & Sienknecht, E. (2020) Ketamine-assisted psychotherapy online? Psychedelic Support.
www.psychedelic.support/resources/ketamine-assisted-psychotherapy-online/
Greenway, K. T., Garel, N., Jerome, L. & Feduccia, A. (2020). Integrating psychotherapy and psychopharmacology: Psychedelic-assisted psychotherapy and other combined treatments. Expert Review of Clinical Pharmacology.
https://doi.org/10.1080/17512433.2020.1772054
Katzman, J. (2018). Rapid depression remission and the “therapeutic bends” with ketamine-assisted psychotherapy. Psychedelics Today.
https://psychedelicstoday.com/2018/09/08/rapid-depression-remission-therapeutic-bends-ketamine-assisted-psychotherapy/
Kew, B. Porter R., Douglas, K., et al. (2023). Ketamine and psychotherapy for the treatment of psychiatric disorders: Systematic review. British Journal of Psychiatry, 9(3). DOI: 10.1192/bjo.2023.53
https://www.cambridge.org/core/journals/bjpsych-open/article/ketamine-and-psychotherapy-for-the-treatment-of-psychiatric-disorders-systematic-review/97614770DE6BC7846763FE19801D412D
Kolp, E., Young, S. M., Freidman, H., et al. (2007). Ketamine-enhanced psychotherapy: Preliminary clinical observations on its effects in treating death anxiety. International Journal of Transpersonal Studies, 26(1), 1–17.
http://dx.doi.org/10.24972/ijts.2007.26.1.1
Mathai, D., Mora, V. & Garcia-Romeu, A. (2022). Toward synergies of ketamine and psychotherapy. Frontiers in Psychology.
https://www.frontiersin.org/articles/10.3389/fpsyg.2022.868103
(2022). Psychedelic psychoanalysis: Transformations of the self. Psychoanalytic Dialogues,32(5), 469-483.
https://doi.org/10.1080/10481885.2022.2106139
Wilkinson, S. T., Wright, D., Fasula, M. K., et al. (2017). Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression. Psychotherapy and Psychosomatics, 86(3), 162–167. DOI: 10.1159/000457960
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516265/
Yermus, R., Bottos, J., Bryson, N., et al. (2024). Ketamine-assisted psychotherapy provides lasting and effective results in the treatment of depression, anxiety, and post-traumatic stress disorder at 3 and 6 months. Psychedelic Medicine. DOI: 10.1089/psymed.2023.0021
https://doi.org/10.1089/psymed.2023.0021
DISSOCIATIVE & PSYCHEDELIC EXPERIENCE
Kolp, E., Friedman, H. L., Krupitsky, E., et al. (2014). Ketamine psychedelic psychotherapy: Focus on its pharmacology, phenomenology, and clinical applications. International Journal of Transpersonal Studies, 33(2), 84-140.
https://doi.org/10.24972/ijts.2014.33.2.84
Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of psychoactive drugs, 29(2), 165-183.
https://doi.org/10.1080/02791072.1997.10400185
Kungurtsev, I. (1991). “Death-rebirth” psychotherapy with ketamine. The Albert Hoffman Foundation Bulletin.
http://whale.to/b/kungurtsev.html
Luckenbaugh, D. A., Niciu, M. J., Ionescu, D. F., et al. (2014). Do the dissociative side effects of ketamine mediate its antidepressant effects? Journal of Affective Disorders, 159, 56-61.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4065787/
Mathai, D., Mathew, S. J., Storch, E. A., & Kosten, T. R. (2018). Revisiting the hallucinogenic potential of ketamine. Psychiatric Times, 35(6).
https://www.psychiatrictimes.com/view/revisiting-hallucinogenic-potential-ketamine
Mathai, D. S., Meyer, M. J., Storch, E. A., & Kosten, T. R. (2020). The relationship between subjective effects induced by a single dose of ketamine and treatment response in patients with major depressive disorder: A systematic review. Journal of Affective Disorders, 264, 123-129.
https://doi.org/10.1016/j.jad.2019.12.023
Nice, M. J., Shovestul, B. J., Jaso, B. A., et al. (2018). Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. Journal of Affective Disorders, 232, 310-315.
https://doi.org/10.1016/j.jad.2018.02.049
GROUP WORK
Dames, S., Kryskow, P. & Watler, C. (2021). A cohort-based case report: The impact of ketamine-assisted psychotherapy embedded in a community of practice framework for healthcare providers with PTSD and depression. Frontiers in Psychiatry, 12. DOI: 10.3389/fpsyt.2021.803279
https://www.frontiersin.org/articles/10.3389/fpsyt.2021.803279/full
Tsang, V. W. L., Tao, B., Dames, S., et al. (2023) Safety and tolerability of intramuscular and sublingual ketamine for psychiatric treatment in the Roots to Thrive ketamine-assisted therapy program: A retrospective chart review. Therapeutic Advances in Psychopharmacology, 13. DOI: 10.1177/20451253231171512
https://journals.sagepub.com/doi/full/10.1177/20451253231171512
FOR YOUNGER & OLDER PATIENTS
Cullen, K. R., Amatya, P., Roback, M. G., et al. (2018). Intravenous ketamine for adolescents with treatment-resistant depression: An open-label study. Journal of Child and Adolescent Psychopharmacology, 28(7), 437-444. DOI: 10.1089/cap.2018.0030
https://www.ncbi.nlm.nih.gov/pubmed/30004254
Gardner, C. (2017). Case report reveals successful treatment of adolescent depression with ketamine. Yale School of Medicine.
https://medicine.yale.edu/news-article/14682/
George, D., Gálvez, V., Martin, D., et al. (2017). Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression. The American Journal of Geriatric Psychiatry, 25(7), 1199-1209. DOI: 10.1016/j.jagp.2017.06.007
https://www.sciencedirect.com/science/article/abs/pii/S1064748117303512?via%3Dihub
Papolos, D., Frei, M., Rosssigtnol, D., et al. (2018). Clinical experience using intranasal ketamine in the longitudinal treatment of juvenile bipolar disorder with fear of harm phenotype. Journal of Affective Disorders, 225, 545-551. DOI: 10.1016/j.jad.2017.08.081
https://www.sciencedirect.com/science/article/abs/pii/S0165032717305888
Turban, J. (2017). The ketamine breakthrough for suicidal children. Scientific American.
https://www.scientificamerican.com/article/the-ketamine-breakthrough-for-suicidal-children/
Zarrinnegar, P., Kothari, J., & Cheng, K. (2019). Successful use of ketamine for the treatment of psychotic depression in a teenager. Journal of Child and Adolescent Psychopharmacology, 29(6), 472-473. DOI: 10.1089/cap.2019.0028
https://www.ncbi.nlm.nih.gov/pubmed/31161948
FOR BIPOLAR DISORDER
Bahji, A., Zarate, C. A. & Vazquez, G. H. (2021). Ketamine for bipolar depression: A systematic review. International Journal of Neuropsychopharmacology, 24(7), 535–541.
https://doi.org/10.1093/ijnp/pyab023
Bennett, R., Yavorsky, C. & Bravo, G. (2022). Ketamine for bipolar depression: Biochemical, psychotherapeutic, and psychedelic approaches. Frontiers in Psychiatry, 13. DOI: 10.3389/fpsyt.2022.867484
https://www.frontiersin.org/articles/10.3389/fpsyt.2022.867484/full
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., et al. (2023). Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Bipolar Disorders.
https://onlinelibrary.wiley.com/doi/10.1111/bdi.13284
FOR POST-TRAUMATIC STRESS DISORDER (PTSD)
Halstead, M., Reed, S., Krause, R. & Williams, M. (2021). Ketamine-assisted psychotherapy for PTSD related to racial discrimination. Clinical Case Studies, 20(4), 310-330.
https://journals.sagepub.com/doi/full/10.1177/1534650121990894
Liriano, F., Hatten, C., & Schwartz, T. L. (2019). Ketamine as treatment for post-traumatic stress disorder: A review. Drugs in Context, 8(212305). DOI: 10.7573/dic.212305
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6457782/
Ross, C., Jain, R., Bonnett, C. J., & Wolfson, P. (2019). High-dose ketamine infusion for the treatment of posttraumatic stress disorder in combat veterans. Annals of Clinical Psychiatry, 31(4), 271-279.
https://www.ncbi.nlm.nih.gov/pubmed/31675388
FOR OBSESSIVE-COMPULSIVE DISORDER (OCD)
Bottemanne, H., & Arnould, A. (2021). Ketamine augmentation of exposure response prevention therapy for obsessive-compulsive disorder. Innovations in clinical neuroscience, 18(10-12), 9–11.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8794478/
Rodriguez, C. I., Kegeles, L. S., Flood, P., & Simpson, H. B. (2011). Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 72(4), 567–569. DOI: 10.4088/JCP.10l06653
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3727240/
Rodriguez, C. I., Wheaton, M., Zwerling, J., Steinman, S. A., Sonnenfeld, D., Galfalvy, H., & Simpson, H. (2016). Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? An open-label trial. The Journal of Clinical Psychiatry, 77(3), 408–409. DOI: 10.4088/JCP.15l10138
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5544939/
FOR EATING DISORDER
Calabrese, L., Scolnick, B., Zupec-Kania, B., et al. (2022). Ketogenic diet and ketamine infusion treatment to target chronic persistent eating disorder psychopathology in anorexia nervosa: A pilot study. Eating and Weight Disorders.
https://doi.org/10.1007/s40519-022-01455-x
Mills, I. H., Park, G. R., Manara, A. R. & Merriman, R. J. (1998) Treatment of compulsive behaviour in eating disorders with intermittent ketamine infusions. QJM International Journal of Medicine, 91(7), 493-503. DOI: 10.1093/qjmed/91.7.493
https://academic.oup.com/qjmed/article/91/7/493/1598067
Skolnick, B., Zupec-Kania, B., Calabrese, L., et al. (2020). Remission from chronic anorexia nervosa with ketogenic diet and ketamine. Frontiers in Psychiatry. DOI: 10.3389/fpsyt.2020.00763
https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00763/full
FOR SUBSTANCE USE DISORDERS (SUD)
Dakwar, E., Anerella, C., Hart, C. L., et al. (2014). Therapeutic infusions of ketamine: Do the psychoactive effects matter? Drug and Alcohol Dependence, 136, 153–157. DOI: 10.1016/j.drugalcdep.2013.12.019
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091719/
Dakwar E., Nunes, E.V., Hart, C.L., et al. (2018) A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study. Neuropharmacology, 142, 270-276. DOI: 10.1016/j.neuropharm.2018.01.005
https://europepmc.org/article/PMC/6033686
Dakwar, E., Nunes, E. V., Hart, C. L., et al. (2019). A single ketamine infusion combined with mindfulness-based behavioral modification to treat cocaine dependence: A randomized clinical trial. American Journal of Psychiatry, 176(11), 923-930.
https://doi.org/10.1176/appi.ajp.2019.18101123
Grabski, M., McAndrew, A., Lawn, W. et al. (2022). Adjunctive ketamine with relapse prevention-based psychological therapy in the treatment of Alcohol Use Disorder. American Journal of Psychiatry.
https://doi.org/10.1176/appi.ajp.2021.21030277
Jones, J. L., Mateus, C. F., Malcolm, R. J., et al. (2018). Efficacy of ketamine in the treatment of substance use disorders: A systematic review. Frontiers in Psychiatry, 9, 277. DOI: 10.3389/fpsyt.2018.00277
https://pubmed.ncbi.nlm.nih.gov/30140240/
Krupitsky, E., Burakov, A., Romanova, T., et al. (2002). Ketamine psychotherapy for heroin addiction: Immediate effects and two-year follow-up. Journal of Substance Abuse Treatment, 23, 273-283. DOI: 10.1016/s0740-5472(02)00275-1
https://www.researchgate.net/publication/10978647_Ketamine_psychotherapy_for_heroin_addiction_Immediate_effects_and_two-year_follow-up
Lalanne, L., Nicot, C., Lang, J. P., et al. (2016). Experience of the use of ketamine to manage opioid withdrawal in an addicted woman: A case report. BMC Psychiatry, 16(1), 395. DOI: 10.1186/s12888-016-1112-2
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5105239/
Rothberg, R., L., Azhari, N., Haug, N. & Dakwar, E. (2020) Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial. Journal of Psychopharmacology. DOI: 10.1177/0269881120970879
https://journals.sagepub.com/doi/abs/10.1177/0269881120970879
FOR SUICIDALITY
Calabrese, L. (2019). Titrated serial ketamine infusions stop outpatient suicidality and avert ER visits and hospitalizations. International Journal of Psychiatry Research, 2(6), 1-12.
http://scivisionpub.com/pdfs/titrated-serial-ketamine-infusions-stop-outpatient-suicidality-and-avert-er-visits-and-hospitalizations-918.pdf
Grunebaum, M. F., Galfalvy, H. C., Choo, T. H., et al. (2018). Ketamine for rapid reduction of suicidal thoughts in major depression. American Journal of Psychiatry, 75(4), 327-335. DOI: 10.1176/appi.ajp.2017.17060647
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880701/pdf/nihms911567.pdf
ARKETAMINE
Zhang, J. C., Yao, W. & Hashimoto, K. (2022). Arketamine, a new rapid-acting antidepressant: A historical review and future directions. Neuropharmacology, 218(109219).
https://doi.org/10.1016/j.neuropharm.2022.109219
ESKETAMINE
Anderson, P. (2019). FDA’s rapid approval of esketamine for severe depression questioned. Medscape.
https://www.medscape.com/viewarticle/921248
Bahji, A., Vazquez, G. H., & Zarate, C. A. (2021). Comparative efficacy of racemic ketamine and esketamine for depression: A systemic review and meta-analysis. Journal of Affective Disorders (278) 542-55. DOI: 10.1016/j.jad.2020.09.071
https://www.sciencedirect.com/science/article/pii/S016503272032766X
Bahji, A., Zarate, C. A., Vazquez, G. H. (2022). Efficacy and safety of racemic ketamine and esketamine for depression: A systematic review and meta-analysis. Expert Opinion on Drug Safety, 853-866. DOI: 10.1080/14740338.2022.2047928
https://pubmed.ncbi.nlm.nih.gov/35231204/
Nikolin, S., Rodgers, A., Schwaab, A, et al. (2023). Ketamine for the treatment of major depression: A systematic review and meta-analysis. eClinicalMedicine, vol 62. DOI: 10.1016/j.eclinm.2023.102127
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430179/pdf/main.pdf
Ramos, M. A., Boyd, W., & Alpert, M. D. (2019). Opinion: The new ketamine-based antidepressant is a rip-off; Johnson & Johnson patented a form of the psychedelic with less research and a ridiculous price tag. VICE.
https://www.vice.com/en_us/article/pajkjy/opinion-the-new-ketamine-based-antidepressant-is-a-rip-off
Ross, E. L. & Soeteman, D. I. (2020). Cost-effectiveness of esketamine nasal spray for patients with treatment-resistant depression in the United States. Psychiatric Services.
https://ps.psychiatryonline.org/doi/10.1176/appi.ps.201900625
MAIL-ORDER KETAMINE
Huet, E. (2022). Online ketamine clinics face tougher times after Covid-era boom. Bloomberg News (11/14/22).
Bloomberg 11-14-22
Love, S. (2021). Psychedelic telemedicine has arrived… What could possibly go wrong? VICE.
https://www.vice.com/en/article/pkpp3k/psychedelic-telemedicine-has-arrived-what-could-possibly-go-wrong
Wilkinson, S. T. & Sanacora, G. (2022). Correspondence: At-home ketamine; still a lot to learn. Journal of Affective Disorders, 318, 150-151. DOI: 10.1016/j.jad.2022.08.090 — Note: This letter was submitted in response to the misleading article by Hull, Malgaroli, Gazzaley, et al (2022).
https://docs-cdn-prod.news-engineering.aws.wapo.pub/publish_document/ffc60069-e959-433d-9a9f-c69a7a582a19/published/ffc60069-e959-433d-9a9f-c69a7a582a19.pdf
EXPLODING KETAMINE INDUSTRY
Crane, M. A.DiStefano, M. J.& Moore, T. J. (2023). False or misleading claims in online direct-to-consumer ketamine advertising in Maryland. JAMA Network Open, 6(11).
https://doi.org/10.1001/jamanetworkopen.2023.42210
Busby, M. (2023). Ketamine clinics have emerged across the US; They’re already going bust. The Guardian.
https://www.theguardian.com/society/2023/apr/11/ketamine-clinics-us-business-safety-mental-health
Thielking, M. (2018). Is the ketamine boom getting out of hand? Scientific American (09/26/18).
https://www.scientificamerican.com/article/is-the-ketamine-boom-getting-out-of-hand/
ADDICTION TO KETAMINE
Friedler, D. (2023). Does the queer scene have a ketamine problem? Rolling Stone.
https://www.rollingstone.com/culture/culture-features/ketamine-queer-scene-addiction-side-effects-1234656422/
TRAINING CLINICIANS
Bennett, R. (2024). Educational pathways for psychedelic practitioners. Journal of Psychedelic Psychiatry, 6(2), 1-6. https://tinyurl.com/bennett-edu-paths